Quantum Biopharma Ltd.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2026 · Filed Aug 13, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · OUTSTANDING SHARE DATA
OUTSTANDING SHARE DATA
The Company is authorized to issue an unlimited number of Class A Multiple Voting Shares and an unlimited number of Class B Subordinate Voting Shares, all without par value. All shares are ranked equally with regards to the Company’s residual assets.
The Class B Subordinate Voting Shares are “restricted securities” within the meaning of such term under applicable Canadian securities laws, as these securities do not carry equal voting rights as compared with the Class A Multiple Voting Shares.
The holders of Class A Multiple Voting Shares are entitled to 276,660 votes per Class A Multiple Voting Share held. Class A Multiple Voting Shares are held by the CEO, President, Co-Chairman of the Board and the Director, Co-Chairman of the Board.
The Company’s outstanding capital was as follows as at the date of this MD&A:
| Class A Multiple Voting Shares | 42 | (1) |
|---|---|---|
| Class B Subordinate Voting Shares | 8,087,479 | (1) |
| Share options | 138,500 | |
| RSUs | 1,600 | |
| Warrants | 719,990 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.